|
|
Value Analysis of Brain Natriuretic Peptide Combined with D-D in Diagnosis and Treatment of Patients with Acute Exacerbation of Interstitial Lung Disease |
LIU Li |
Guang'an Hospital, Huaxi, Sichuan University, Sichuan Guang'an638500, China |
|
|
Abstract Objective: To study and analyze the diagnostic value of brain natriuretic peptide combined with D- two (D-D) in patients with acute exacerbation of interstitial lung disease. Methods: From June 2015 to August 2016, 50 patients with acute exacerbation of interstitial lung disease were treated in our hospital. The death group was divided into 28 cases in the death group and 22 in the survival group. Brain natriuretic peptide and D-D levels were detected in all patients. Baseline data, brain natriuretic peptide and D-D levels, clinical symptoms and signs, serum IL-6 and C reactive protein levels were compared between the two groups. Results: There was no significant difference in the sex, weight, age and past medical history between the death group and the survival group (P > 0.05). The brain natriuretic peptide and D-D level in the death group were (744.6 + 248.2) ng/ml and (4245.5 + 1584.2) pg/ml respectively, which were all higher than those of the survival group (32.5 + 10.3) ng/ml and (425.3 + 242.5) pg/ml, all of which were significantly different (P < 0.05). Death group of patients with dyspnea, hemoptysis, fever, chest pain, syncope, lower extremity edema and lung wet incidence rale were 82.14% (23/28), 28.57% (8/28), 67.86% (19/28), 42.86% (12/28), 39.29% (11/28), 50.00% (14/28), 100.00% (28/28), were higher than in survival group 50.00% (11/22), 4.55% (1/22), 18.18% (4/22), 13.64% (3/22), 13.64% (3/22), 18.18% (4/22), 54.55% (12/28), all had significant differences (all P < 0.05). Death patients serum IL - 6 and C - reactive protein levels respectively was (13.1±2.6)ng/L, (137.8±11.6) mg/L, were higher than in survival group (6.5±3.5 )ng/L, (9.6±6.1) mg/L, all have significant differences (all P < 0.05). Conclusions: In clinical work, the brain natriuretic peptide and D-D level can be used to predict the acute exacerbation of interstitial lung disease, and can be known as an effective indicator of the prognosis of patients with acute exacerbation of interstitial lung disease.
|
|
|
|
|
[1] Mukhopadhyay R,Joaquin J,Hogue R,et al.Complete genome sequence of dolosigranulum pigrum from a patient with interstitial lung disease using single-molecule real-time sequencing technology[J].Genome Announc,2017,5(18):317~318. [2] 朱力华.糖皮质激素治疗间质性肺疾病急性加重期患者的临床疗效[J].中国药物经济学,2016,11(11):62~64. [3] 熊国芳,卢晓杰.糖皮质激素治疗间质性肺疾病急性加重的疗效评价[J].临床医药文献电子杂志,2016,3(2):301~304. [4] 董文,黄奕江,吴海洪,等.内科胸腔镜肺活检对弥漫性间质性肺疾病诊断价值及安全性分析[J].中国内镜杂志,2016,22(2):95~98. [5] 王冉冉,田美伊,杨金水,等.血清KL-6水平对评价结缔组织病间质性肺疾病作用的研究[J].中国临床医生杂志,2017,45(3):36~40. [6] 葛启隆,林春龙.支气管肺泡灌洗液在间质性肺疾病中的应用进展[J].医学综述,2017,23(4):708~712. [7] 朱维维,李一丹,李虹,等.间质性肺疾病肺超声表现与心脏受累程度之间的相关性研究[J].中华超声影像学杂志,2016,25(9):743~749. [8] 葛南海,蔡孝桢,肖长长,等.夜间无创正压通气对重度-极重度慢性阻塞性肺疾病相关肺动脉高压的影响[J].中国现代药物应用,2017,11(1):49~51. [9] 唐纯丽,罗群,谢佳星,等.间质性肺疾病合并肺栓塞12例的临床特征分析[J].国际呼吸杂志,2015,35(4):270~273. |
|
|
|